Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096039 · ClinicalTrials.gov registry record
Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,614,719
- Enrollment target
NCT05096039: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05096039 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,614,719 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096039 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,614,719 participants
- Enrollment target
Study Summary
This study evaluated the association between sacubitril/valsartan utilization and HF patients' Part A \& B expenditures within the reimbursement framework of BPCI and MSSP, and identified BPCI/MSSP participants with the greatest potential for performance improvement (with respect to improving quality and efficiency of care for HF patients) through optimized utilization of sacubitril/valsartan.
Primary Outcome
BPCI CHF episode costs defined as the sum of expenditures for Part A \& B covered medical services during the CHF episode
Interventions
- DRUG Sacubitril/valsartan
- DRUG ACEI or ARB and no sacubitril/valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,614,719 participants |
| Start Date | 2020-04-10 |
| Est. Completion | 2020-09-30 |
What the finished NCT05096039 record still lists
NCT05096039 is an observational study that tracks outcomes without assigning an intervention. Its 1,614,719 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Sacubitril/valsartan is the first listed.
NCT05096039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05096039 about?
NCT05096039 is a clinical study titled "Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models". This study evaluated the association between sacubitril/valsartan utilization and HF patients' Part A \& B expenditures within the reimbursement framework of BPCI and MSSP, and identified BPCI/MSSP participants with the greatest potential for performance improvement (with respect to improving qualit...
What is the current status of trial NCT05096039?
This trial is currently completed. The enrollment target is 1,614,719 participants. The study started on 2020-04-10. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT05096039?
The interventions under investigation include: Sacubitril/valsartan (DRUG), ACEI or ARB and no sacubitril/valsartan (DRUG).
Who is sponsoring clinical trial NCT05096039?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
- NCT07022951 · 1,200,000 participants
The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI